Orchestra BioMed Holdings, Inc. (OBIO)
After hours:
| Previous close | 4.4400 |
| Open | 4.4700 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 4.3800 - 4.5900 |
| 52-week range | 4.2200 - 20.1900 |
| Volume | |
| Avg. volume | 46,949 |
| Market cap | 157.103M |
| Beta (5Y monthly) | 0.14 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.4800 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 16.33 |
Simply Wall St.Orchestra BioMed Holdings Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag
Orchestra BioMed Holdings ( NASDAQ:OBIO ) Full Year 2023 Results Key Financial Results Net loss: US$49.1m (loss widened...
GlobeNewswireOrchestra BioMed Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update
Initiated enrollment of the BACKBEAT global pivotal study evaluating AVIM therapy (also known as BackBeat Cardiac Neuromodulation Therapy) in hypertensive pacemaker patients in collaboration with Medtronic, plc (NYSE: MDT) in December 2023 Orchestra BioMed and Terumo remain actively engaged to update operational plans and financial arrangements for Virtue® Sirolimus AngioInfusionTM Balloon (“SAB”) development and commercialization for treatment of coronary and peripheral artery diseaseExpected r
- GlobeNewswire
Orchestra BioMed Announces Appointment of Medical Device Industry Expert David Pacitti to Board of Directors
David Pacitti is currently the President of Siemens Medical Solutions USA, Inc. and Head of the Americas, Siemens Healthineers; formerly Division Vice President of U.S. Commercial Operations, Sales, and Marketing at Abbott VascularMr. Pacitti brings nearly 30 years of experience in cardiovascular device and procedural imaging experience to the Orchestra BioMed Board of Directors after previously serving as a strategic advisor during the formation of the company NEW HOPE, Pa., March 26, 2024 (GLO
